Skip to main content

FDA Expands Approval of Omnipod 5 Insulin Delivery System to Include Patients With Type 2 Diabetes

By Physician’s Briefing Staff HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 28, 2024.

via HealthDay

TUESDAY, Aug. 27, 2024 -- On Monday, the U.S. Food and Drug Administration approved the Insulet Omnipod 5 insulin delivery system for patients with type 2 diabetes. It is the first such system for use by people with the more prevalent form of the disease.

The FDA first signed off on the system, which automatically adjusts insulin delivery as needed, for type 1 diabetes in 2022. In approving Insulet's Omnipod 5 insulin delivery system for type 2 diabetes patients, the FDA said the clearance "provides a new option that can automate many of these manual tasks [of tracking and managing blood glucose levels], potentially reducing the burden of living with this chronic disease."

"The FDA has long worked with the diabetes community to ensure access to additional options and flexibilities for diabetes management," Michelle Tarver, M.D., acting director of the FDA Center for Devices and Radiological Health, said in a news release announcing the expanded use. "The FDA is committed to advancing new device innovation that can improve the health and quality of life for people living with chronic diseases that require day-to-day maintenance like diabetes."

Insulet applauded the expanded approval.

"Today's announcement represents a significant milestone in providing easy-to-use, patient-centric technology for the treatment of type 2 diabetes," Insulet CEO Jim Hollingshead said in a company news release.

With the new system, the wearable product provides up to three days of nonstop insulin delivery without the need to handle a needle. The Omnipod 5 works in concert with a continuous glucose monitor to manage blood glucose with no daily injections and no finger pricks.

In approving the expanded use, the FDA reviewed data from a clinical study of 289 individuals 18 years and older with type 2 diabetes for 13 weeks. Volunteers' blood glucose control improved, and these improvements were seen across all demographic groups. Adverse events were generally mild to moderate and included hyperglycemia, hypoglycemia, and skin irritation.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

American Diabetes Association, June 20-23

The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than 15,000 participants, including clinicians...

Muscle Ultrasound Can Detect Insulin Resistance

MONDAY, June 30, 2025 -- Muscle ultrasound can detect insulin resistance and lower muscle mass, according to a study published online June 12 in the Journal of Ultrasound...

Disparities Seen in Continuous Glucose Monitor Rx by Language Preference

FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.